Effect of Renin Angiotensin Aldosterone System Genetic Polymorphism on the Pharmacological Effect of Mineralocorticoid Receptor Antagonists in Patients With Myocardial Infarction - Trial NCT05873400
Access comprehensive clinical trial information for NCT05873400 through Pure Global AI's free database. This phase not specified trial is sponsored by Ain Shams University and is currently Recruiting. The study focuses on Myocardial Infarction. Target enrollment is 102 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Ain Shams University
Timeline & Enrollment
N/A
Aug 01, 2022
Apr 01, 2024
Primary Outcome
Genetic polymorphism
Summary
Early treatment of Myocardial Infarction patients with mineralocorticoid receptor antagonist
 with help reduces the incidence of cardiac remodeling and development into heart failure.
 Also studying aldosterone synthase (CYP11B2) and mineralocorticoid receptor (NR3C2) gene
 polymorphisms in Egyptian Myocardial Infarction patients will help tailor medication therapy
 and optimize therapeutic effects with the least adverse effects.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05873400
Non-Device Trial